Erythrocyte rigidity and clot pathology in JAK2-MPN
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-10-07 — Aberrant erythrocyte rigidity in JAK2myeloproliferative neoplasms underlies concurrent thrombosis and hemorrhage.: Preclinical mechanistic study proposes JAK2V617F induces intrinsic erythrocyte membrane/cytoskeletal rigidity that impairs clot contraction, producing larger but mechanically unstable thrombi — a unifying mechanism for the concurrent thrombosis–hemorrhage paradox in MPN. (novelty: 5)
Open questions
Related
Contributing findings
Aberrant erythrocyte rigidity in JAK2myeloproliferative neoplasms underlies concurrent thrombosis and hemorrhage.
07-oct-2026
novelty 5
per-area 5
introduces